Evidence map›Paper›PMID 33173219›Full record

ArticleScientific reports2020

Mir142 loss unlocks IDH2

A Marshall, J Kasturiarachchi, P Datta, Y Guo, E Deltcheva, C James, J Brown, G May, N Anandagoda, I Jackson and 10 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The LeukemicCancers · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Consequences of genetic variants in miRNA genes.Computational and structural biotechnology journal · 2022
    Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

A Marshall *UCL Cancer Institute, University College London, London, UK.
J Kasturiarachchi *UCL Cancer Institute, University College London, London, UK.
P DattaUCL Cancer Institute, University College London, London, UK.
Y GuoUCL Cancer Institute, University College London, London, UK.
E DeltchevaUCL Cancer Institute, University College London, London, UK.
C JamesUCL Cancer Institute, University College London, London, UK.
J BrownUCL Cancer Institute, University College London, London, UK.
G MayUCL Cancer Institute, University College London, London, UK.
N AnandagodaSchool of Immunology and Microbial Sciences, King's College London, London, UK.
I JacksonSchool of Immunology and Microbial Sciences, King's College London, London, UK.
J K HowardSchool of Life Course Sciences, King's College London, London, UK.
E GhazalyCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
S BrooksUCL Cancer Institute, University College London, London, UK.
A KhwajaUCL Cancer Institute, University College London, London, UK.
M ArakiInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
K ArakiInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
D LinchUCL Cancer Institute, University College London, London, UK.
G M LordFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
T EnverUCL Cancer Institute, University College London, London, UK.
R NimmoUCL Cancer Institute, University College London, London, UK. r.nimmo@oxb.com.
CRUK Lung Cancer Centre of Excellence · GBUniversity College London · GBKing's College London · GBKumamoto University · JPQueen Mary University of London · GBUniversity of Manchester · GB

Funding

British Heart Foundation PG/12/36/29444Cancer Research UK 12796Cancer Research UK 163011Cancer Research UK C416/A20938Medical Research Council MR/N000838/1Wellcome TrustWellcome Trust 107387/Z/15/Z
6 · The paper itself

Abstract

AML is a genetically heterogeneous disease and understanding how different co-occurring mutations cooperate to drive leukemogenesis will be crucial for improving diagnostic and therapeutic options for patients. MIR142 mutations have been recurrently detected in IDH-mutated AML samples. Here, we have used a mouse model to investigate the interaction between these two mutations and demonstrate a striking synergy between Mir142 loss-of-function and IDH2

Indexed as

AnimalsCarcinogenesisCell Line, TumorFemaleGene Expression Regulation, LeukemicGenotypeHomeodomain ProteinsHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMiceMicroRNAsMutationHomeodomain ProteinsIsocitrate DehydrogenaseMicroRNAsMirn142 microRNA, mouse

Identifiers

PMID33173219
PMCPMC7656267
OpenAlexW3100501898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.